Journal
DIABETES OBESITY & METABOLISM
Volume 20, Issue 7, Pages 1793-1797Publisher
WILEY
DOI: 10.1111/dom.13268
Keywords
clinical trial; fatty liver; insulin resistance; NAFLD; resveratrol
Categories
Funding
- University Hospital of Tubingen, Germany
- DSM Nutritional Products, Kaiseraugst, Ltd, Switzerland
- Deutsches Zentrum fur Diabetesforschung (DZD e.V.)
Ask authors/readers for more resources
We performed the largest randomized, placebo-controlled clinical trial to date (N = 112, 12-week intervention) to investigate the effects and safety of resveratrol supplementation on liver fat content and cardiometabolic risk parameters in overweight and obese and insulin-resistant subjects. At baseline the variability in liver fat content was very large, ranging from 0.09% to 37.55% (median, 7.12%; interquartile range, 3.85%-12.94%). Mean (SD) liver fat content was 9.22 (6.85) % in the placebo group and 9.91 (7.76) % in the resveratrol group. During the study liver fat content decreased in the placebo group (-0.7%) but not in the resveratrol group (-0.03%) (differences between groups: P = .018 for the intention-to-treat [ITT] population; N = 54, resveratrol, N = 54, placebo and P = .0077 for the per protocol [PP] population). No effects of resveratrol supplementation on cardiometabolic risk parameters were observed. Resveratrol supplementation was well tolerated and safe. In conclusion, these data suggest that resveratrol supplementation is safe and that it does not considerably impact liver fat content or cardiometabolic risk parameters in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available